Comparative Pharmacology
Head-to-head clinical analysis: MAGNESIUM SULFATE IN DEXTROSE 5 IN PLASTIC CONTAINER versus POTASSIUM CHLORIDE 0 11 IN DEXTROSE 10 AND SODIUM CHLORIDE 0 2 IN PLASTIC CONTAINER.
Peer-Reviewed Evidence
Head-to-head clinical analysis: MAGNESIUM SULFATE IN DEXTROSE 5 IN PLASTIC CONTAINER versus POTASSIUM CHLORIDE 0 11 IN DEXTROSE 10 AND SODIUM CHLORIDE 0 2 IN PLASTIC CONTAINER.
MAGNESIUM SULFATE IN DEXTROSE 5% IN PLASTIC CONTAINER vs POTASSIUM CHLORIDE 0.11% IN DEXTROSE 10% AND SODIUM CHLORIDE 0.2% IN PLASTIC CONTAINER
Comparing the clinical profiles, pharmacokinetic behaviors, and safety indices of these two therapeutic agents.
Magnesium sulfate provides magnesium ions, which are essential for various physiological processes. It acts as a cofactor for enzymatic reactions, stabilizes excitable membranes, and antagonizes calcium entry at the neuromuscular junction, leading to reduced acetylcholine release and muscle relaxation. In the CNS, it may act as a noncompetitive antagonist of NMDA receptors, exerting anticonvulsant effects.
Potassium chloride provides potassium ions for maintenance of electrolyte balance and cellular function; dextrose provides a source of calories and may stimulate insulin secretion, which facilitates intracellular potassium uptake; sodium chloride provides sodium ions for maintenance of fluid and electrolyte balance.
1 to 4 g intravenously as a 5% to 20% solution, rate not exceeding 150 mg/min; dosing frequency depends on indication (e.g., preeclampsia/eclampsia: 4-5 g IV loading then 1-2 g/hr infusion; hypomagnesemia: 1-2 g IV over 1-2 hours, may repeat based on serum magnesium levels).
Adult: Intravenous infusion at a rate determined by fluid and electrolyte needs; typical dose for maintenance is 1-2 L/day providing approximately 20-40 mEq potassium, 34-68 g dextrose, and 4-8 g sodium chloride per day. Administration rate not to exceed 10 mEq/h of potassium.
None Documented
None Documented
Terminal half-life approximately 4-5 hours in normal renal function; prolonged in renal impairment (up to 40 hours).
Potassium: no defined terminal half-life due to tight homeostatic regulation; dextrose: minutes (insulin-mediated clearance); sodium: regulated by renal excretion.
Primarily renal (90-100% as unchanged magnesium). Less than 1% biliary/fecal.
Potassium is primarily excreted renally (90%) with minimal fecal loss; dextrose and sodium are fully metabolized or excreted renally.
Category C
Category A/B
Electrolyte
Electrolyte